PURE Bioscience Announces Pricing of Public Offering of 3,784,000 Shares of Common Stock

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the pricing of an underwritten public offering of 3,784,000 shares of its common stock, offered at a price to the public of $1.10 per share. The gross proceeds to PURE from this offering are expected to be $4,162,400, before deducting the underwriting discount and other estimated offering expenses payable by PURE. PURE has granted the underwriters a 45-day option to purchase at the public offering price up to an aggregate of 567,600 additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about September 17, 2012, subject to customary closing conditions.